Table. Cryptococcus spp. strains used in this study*.
| Strain† | Mating type‡/serotype | AFLP/M13 genotype§ | Source | Country |
|---|---|---|---|---|
| CBS9172 | aA | AFLP1/VNI | Soil sample from garden of patient with neighboring bird colonies | Italy |
| CBS8710 (H99) | αA | AFLP1/VNI | Patient with Hodgkin disease | United States |
| CBS1622 | αB | AFLP4/VGI | Tumor | France |
| CBS6992 | αB | AFLP4/VGI | Human | Unknown |
| E566 | aB | AFLP4/VGI | Eucalyptus camaldulensis | Australia |
| CBS10510 (WM276) | αB | AFLP4/VGI | Debris of E. tereticornis | Australia |
| CBS10488 (AMC770616) | αBaD | AFLP8/NA | Human CSF | The Netherlands |
| CBS10489 (AMC2010404) | αBaD | AFLP8/NA | Human CSF | The Netherlands |
| CBS10490 (AMC2011225) | αBaD | AFLP8/NA | Human CSF | The Netherlands |
| CBS10496 (LSPQ#308) | αA–B | AFLP9/NA | Blood of an HIV-positive patient | Canada |
*AFLP, amplified fragment length polymorphism; CBS, Fungal Biodiversity Centre; AMC, Netherlands Reference Laboratory for Bacterial Meningitis, Academic Medical Center, Amsterdam, the Netherlands; NA, not applicable; CSF, cerebrospinal fluid. †Origin and genetic composition of the strains are indicated. ‡ –, mating type unknown. §AFLP fingerprint genotype (7), followed by corresponding M13 PCR fingerprint genotype (8).